Amicus Therapeutics Inc

Amicus Therapeutics — FY2022 Earnings Presentation

29 slides from Amicus Therapeutics's earnings presentation, Mar 1, 2023

  1. Slide 1: FY22 Financial Results Conference Call & Webcast

    A T T H E F O R E F R O N T O F T H E R A P I E S F O R R A R E D I S E A S E S FY22 Financial Results Conference Call & Webcast March 1, 2023

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

  3. Slide 3: A Rare Company

    3 A Rare Company Patient-dedicated, rare disease biotechnology company with sustained double-digit revenue growth, a global commercial infrastructure, and late-stage development capabilities GLOBAL COMMERCIAL ORGANIZATION EMPLOYEES in 20 Countries GALAFOLD & AT-GAA Gene Therapy Platform Leveraging E

  4. Slide 4: 2023 Strategic Priorities

    2023 Strategic Priorities Sustain double-digit Galafold revenue growth of 12-17% at CER1 Secure FDA, EMA, and MHRA approvals for AT-GAA Initiate successful global launches of AT-GAA Advance best-in-class, next-generation Fabry and Pompe pipeline programs and capabilities Maintain strong financial po

  5. Slide 5: Galafold (migalastat) Continued Growth

    5 Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease

  6. Slide 6: 2022 Galafold Success

    6 2022 Galafold Success (as of December 31, 2022) Building on Galafold’s success and leveraging leadership position to drive continued growth Galafold is indicated for adults with a confirmed diagnosis of Fabry disease and an amenable variant. The most common adverse reactions reported with Galafold

  7. Slide 7: Galafold Performance

    7 Galafold Performance 2022 reported revenue growth of +8% to $329M – Strong operational growth of +16% at CER ▪ Global 3-month net new patients trend highest in 2 years ▪ ~50% share of treated amenable patients ▪ Interactions with HCPs increasing from same period last year ▪ Healthy global mix of s

  8. Slide 8: Galafold Quarterly Trends

    8 Galafold Quarterly Trends Growth remains strong with Q4 revenue of $88M and FY22 revenue of $329M $79M $82M $79M $81M $82M $88M 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 Quarterly Galafold Sales ▪ Expect non-linear quarterly growth to continue due to uneven ordering patterns and FX fluctuations Distribution o

  9. Slide 9: Galafold Global Launch Momentum

    9 Galafold Global Launch Momentum (as of December 31, 2022) Strong patient demand with 2,000+ individuals treated with Galafold and performance against key metrics lay the foundation for continued double-digit growth in 2023 9 Continued penetration into existing markets Further uptake in diagnosed u

  10. Slide 10: AT-GAA Launch Preparations

    10 AT-GAA Launch Preparations Experienced and passionate rare disease medical and commercial organization poised for second successful launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease treatment centers Development of educational materials Pl

  11. Slide 11: AT-GAA (cipaglucosidase alfa + miglustat)

    11 AT-GAA (cipaglucosidase alfa + miglustat) Potential to establish a new standard of care for people living with Pompe disease

  12. Slide 12: Pompe Disease Overview

    12 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality Estimated inc

  13. Slide 13: AT-GAA: Global Regulatory Status

    13 13 1Data on file AT-GAA: Global Regulatory Status Anticipate regulatory approvals and launch into the three largest Pompe markets in 2023 ▪ Pombiliti™ (cipaglucosidase alfa) European Commission (EC) decision expected in 1Q 2023 ▪ Miglustat CHMP opinion expected in 2Q 2023 with EC decision anticip

  14. Slide 14: AT-GAA: Ongoing Clinical Studies and Expanded Access Mechanisms

    14 AT-GAA: Ongoing Clinical Studies and Expanded Access Mechanisms ▪ Ongoing clinical studies in children and adolescents1 with LOPD as well as in Infantile-Onset Pompe Disease (IOPD) ▪ Multiple expanded access mechanisms in place, including in the U.S., U.K., Germany, France, Japan, and others ▪ ~2

  15. Slide 15: WORLDSymposium Update

    15 WORLDSymposium Update Number of patients (n) Mean (SD) baseline 6MWD (% predicted): Cipa/mig–cipa/mig = 56.1 (16.03) Alg/pla–cipa/mig = 54.8 (17.68) Mean (SD) week 104 6MWD (% predicted): Cipa/mig–cipa/mig = 60.8 (18.07) Alg/pla–cipa/mig = 54.3 (21.86) 6 Cipa/mig–cipa/mig Cipa/mig Alg/pla Baselin

  16. Slide 16: Corporate Outlook

    16 Corporate Outlook Delivering on our mission for patients and shareholders

  17. Slide 17: 2022 Select Financial Results

    17 2022 Select Financial Results 2022 revenue of $329M and growth rate of 16% at CER from global Galafold sales (in thousands, except per share data) Dec. 31, 2022 Dec. 31, 2021 Product Revenue $329,233 $305,514 Cost of Goods Sold 38,599 34,466 R&D Expense 276,677 272,049 SG&A Expense 213,041 192,71

  18. Slide 18: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear strategy to build our business, advance our portfolio, and achieve profitability 18 Sustain Galafold Revenue Growth Deliver on Financial Goals Secure Approvals of AT-GAA $329M FY22 revenue, +16% YoY operational growth 2023 Galafold revenue growth gui

  19. Slide 19: Positioned for Significant Value Growth

    19 Positioned for Significant Value Growth Focused on execution and driving sustainable double-digit revenue growth on path to profitability Continue to bring Galafold® to as many patients as possible, sustain double-digit operational revenue growth Successful launch of AT-GAA for people living with

  20. Slide 20: Appendix

    herapeutics Appendix

  21. Slide 21: Reconciliation of Non-GAAP Financial Measures

    Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures Total operating expenses - as reported GAAP Research and development: Share-based compensation Selling, general and administrative: Share-based compensation Loss on impairment of assets Changes in fair value of continge

  22. Slide 22: Environmental, Social, & Governance (ESG) Snapshot

    22 Environmental, Social, & Governance (ESG) Snapshot Board of Directors Eco-friendly decision-making has unearthed economic efficiencies while continuing to bolster our standing as a good corporate citizen. Committed to ongoing Board refreshment and diversity of background, gender, skills, and expe

  23. Slide 23: FX Sensitivity and Galafold Distribution of Quarterly Sales

    23 FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q4 2022 Currency Variances: USD/ Q4 2021 Q4 2022 Variance EUR 1.144 1.021 (10.7%) GBP 1.348 1.174 (12.9%) JPY 0.009 0.007 (19.5%) Full Year 2023 Revenue Sensitivity Given the high proportion of Amicus revenue

  24. Slide 24: Amicus Pipeline

    24 I N D I C A T I O N D I S C O V E R Y P R E C L I N I C A L P H A S E 1 / 2 P H A S E 3 R E G U L A T O R Y C O M M E R C I A L F A B R Y F R A N C H I S E Galafold®(migalastat) Fabry Gene Therapy Next-Generation Chaperone P O M P E F R A N C H I S E AT-GAA (cipaglucosidase alfa + miglustat) Pomp

  25. Slide 25: AT-GAA Phase 3 PROPEL Study Results

    25 AT-GAA Phase 3 PROPEL Study Results Clinically meaningful outcomes from Phase 3 PROPEL study provide the basis for global regulatory submissions of AT-GAA

  26. Slide 26: WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD: 6MWD

    26 WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD Improvement from the PROPEL baseline in % predicted 6MWD for the cipa/mig group was maintained throughout the OLE for ERT-experienced and ERT-naïve patients • ERT-experienced and -naïve patients treated with cipa/mig throughout showed durable

  27. Slide 27: WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD: FVC

    27 WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD Sitting % predicted FVC remained stable in ERT-experienced and ERT-naïve patients throughout the OLE for both PROPEL treatment groups • ERT-experienced patients treated with cipa/mig throughout remained stable, while patients who received alg/

  28. Slide 28: WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD: Serum CK

    28 WORLDSymposium Update – Phase 3 OLE of AT-GAA in LOPD Cipa/mig treatment was associated with a durable reduction in serum CK during PROPEL and the OLE in both ERT-experienced and ERT-naïve patients • ERT-experienced and -naïve patients treated with cipa/mig throughout showed a decline in serum CK

  29. Slide 29: Urine Hex4 levels in PROPEL and OLE

    29 • ERT-experienced patients treated with cipa/mig throughout experienced a decline in urine Hex4 levels in PROPEL that stabilized during the OLE. ERT-experienced patients who received alg/pla in PROPEL experienced an increase in Hex4 and a marked decline after switching to cipa/mig in the OLE • ER

Amicus Therapeutics — FY2022 Earnings Presentation on 6ix